AI抗病毒新药研发冷门却是刚需

Core Viewpoint - The article discusses the acceleration of AI-driven drug development in the biopharmaceutical sector, particularly focusing on the challenges and opportunities in developing antiviral drugs for infectious diseases, which are often overlooked compared to oncology and autoimmune disease research [3]. Group 1: AI in Drug Development - AI platforms can design drug molecules for infectious diseases as well as for oncology and neurodegenerative diseases, with the priority of investment being crucial [5]. - The "AI Kongming" platform, developed by GHDDI, integrates various AI algorithms to enhance the drug development process, achieving significant improvements in candidate molecule hit rates and optimization efficiency compared to traditional methods [6][7]. - The platform has successfully generated and validated novel chemical structures for tuberculosis, achieving a hit rate of approximately 38% for biologically active compounds [6]. Group 2: Challenges in Infectious Disease Drug Development - The development of antiviral drugs faces numerous challenges, including high research costs, uncertain commercial returns, and the rapid mutation of viruses leading to drug resistance [3]. - The need for collaboration among governments, enterprises, and research institutions is emphasized due to the sporadic nature of infectious diseases and the complexity of viral characteristics [8]. - AI can significantly enhance the efficiency of drug development processes, particularly in toxicity optimization, which traditionally takes 2-3 years, potentially reducing this timeline to about six months [10]. Group 3: Future of AI in Drug Development - AI's role in drug development is not limited to generating drug candidates but also involves creating tools that assist scientists in integrating biological and chemical knowledge into the drug development process [12]. - The success rate of AI-generated drug molecules in Phase I clinical trials is reported to be between 80% and 90%, significantly higher than the traditional success rate of 50% [13]. - The future of AI in drug development is viewed positively, with expectations that it will reduce reliance on animal models and improve the predictive capabilities for drug efficacy and safety [16].